Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
Tuspetinib for AML
Expanded Access
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Join Us
Values & Culture
Perks & Benefits
Explore Careers
Contact
Posters & Presentations
Product Pipeline
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
All
Poster
Presentation
April 1, 2019
Poster
2019 AACR Poster - Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in Raji B cells
2019 AACR Poster - Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in Raji B cells:
View Poster
December 12, 2018
Presentation
Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers
Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers:
View Presentation
December 2, 2018
Poster
2018 ASH Poster – CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells
2018 ASH Poster – CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells:
View Poster
December 2, 2018
Poster
2018 ASH Poster – Concomitant Targeting of FLT3 and BTK with CG-806 Overcomes FLT3-Inhibitor Resistance Through Inhibition of Autophagy
2018 ASH Poster – Concomitant Targeting of FLT3 and BTK with CG-806 Overcomes FLT3-Inhibitor Resistance Through Inhibition of Autophagy:
View Poster
June 15, 2018
Poster
2018 EHA Poster - CG-806, a Non Covalent Pan-FLT3/Pan-BTK Inhibitor, Exhibits Unique Binding to Wild Type and C481S Mutant BTK and Greater Potency Than Ibrutinib Against Malignant B Cells
2018 EHA Poster - CG-806, a Non Covalent Pan-FLT3/Pan-BTK Inhibitor, Exhibits Unique Binding to Wild Type and C481S Mutant BTK and Greater Potency Than Ibrutinib Against Malignant B Cells:
View Poster
April 17, 2018
Poster
APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency
APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency:
View Poster
April 15, 2018
Poster
2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples
2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples:
View Poster
April 15, 2018
Poster
2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro
2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro:
View Poster
December 11, 2017
Poster
2017 ASH Poster - CG’806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition as a Single Agent and in Combination with a BET Bromodomain Inhibitor and a Bcl2 Inhibitor Against AML and CLL Patient Samples
2017 ASH Poster - CG’806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition as a Single Agent and in Combination with a BET Bromodomain Inhibitor and a Bcl2 Inhibitor Against AML and CLL Patient Samples:
View Poster
Previous
1
2
3
4
5
6
7
8
Next